Twenty-four vs. fourty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in Interferon alpha monotherapy relapsers with chronic hepatitis c

BSE August-Jörg; R Hermann; M Weitz; E Renner

doi:10.4414/smw.2003.10300

Original article

Vol. 133 No. 3334 (2003)

Twenty-four vs. fourty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in Interferon alpha monotherapy relapsers with chronic hepatitis c

BSE August-Jörg
R Hermann
M Weitz
E Renner

Fulltext PDF

DOI: https://doi.org/10.4414/smw.2003.10300
Cite this as:: Swiss Med Wkly. 2003;133:455-460
Published: 23.08.2003

How to Cite

1.

August-Jörg B, Hermann R, Weitz M, Renner E. Twenty-four vs. fourty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in Interferon alpha monotherapy relapsers with chronic hepatitis c. Swiss Med Wkly [Internet]. 2003 Aug. 23 [cited 2024 Nov. 30];133(3334):455-60. Available from: https://smw.ch/index.php/smw/article/view/299

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.